Medicus Pharma Ltd. Common Stock

MDCX · NASDAQ · Healthcare / Drug Manufacturers - General

1.95USD+0.23 (+13.37%)

Price History

Full chart

Market Stats

Previous Close1.72

Open1.75

Day Range1.70 – 2.00

52-Week Range0.144 – 2.78

Volume47.99K

Market Cap10.93M

P/E (TTM)0.00

Forward P/E0.00

EPS-2.36

Dividend Yield0.00%

Beta-0.48

50-Day Avg0.2618

200-Day Avg0.6613

About

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - General
CEODr. Raza Bokhari M.B.A., M.D.
Employees16
Headquarters300 Conshohocken State Road, West Conshohocken, PA, United States, 19428, USA
Websitehttps://medicuspharma.com

Leadership

Dr. Raza Bokhari M.B.A., M.D.CEO & Executive Chairman · b. 1968
Dr. Edward J. Brennan Jr., F.A.C.S., M.D.Chief Scientific Officer and Head of R&D Program · b. 1961
Dr. Faisal Mehmud M.D.Chief Medical Officer · b. 1975
Mr. Andrew Alasdair SmithChief Operating Officer · b. 1969
Ms. Anna Baran-Djokovic J.D.Senior Vice President of Investor Relations
Ms. Viktoria SlepeniukSenior Vice President of Public Relations
Ms. Maryann AdessoChief of Staff & Corporate Secretary

Financials

Income Statement

Currency: USD	2010-12-31	2015-12-31	2016-12-31	2017-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	12.64M	0	0	0	0	0	0	0	0
Growth (%)	-	-100.00%	-	-	-	-	-	-	-
Cost of Revenue	11.30M	0	0	0	-	-	-	-	-
Gross Profit	1.34M	0	0	0	-	-	-	-	-
Gross Margin	10.61%	-	-	-	-	-	-	-	-
Operating Expense	1.85M	3.42K	5.77K	136.36K	-	-	-	-	-
Operating Income	-505.83K	-3.42K	-5.77K	-136.36K	-1.44M	-978.42K	-4.73M	-11.18M	-18.35M
Operating Margin	-4.00%	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-1.94M	-1.17M	-586.78K	-11.16M	-25.23M
Net Income	-693.76K	-3.42K	-5.77K	-138.89K	-2.06M	-1.69M	-5.31M	-11.16M	-25.37M
Net Income Margin	-5.49%	-	-	-	-	-	-	-	-
R&D	-	-	-	-	1.18M	646.38K	193.58K	3.53M	7.72M
Interest Expense	0	0	0	0	115.41K	526.83K	595.54K	317.54K	141.26K
Interest Expense % of Total Revenue	0.00%	-	-	-	-	-	-	-	-

Balance Sheet

Currency: USD	2010-12-31	2015-12-31	2016-12-31	2017-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	3.00M	-	-	40.58K	78.51K	282.65K	1.89M	5.65M	10.06M
Total Liabilities	5.00M	3.42K	9.18K	103.23K	10.58M	12.48M	781.61K	2.51M	10.02M
Total Equity	-2.00M	-	-	-62.65K	-10.51M	-12.20M	1.11M	3.13M	-67.55K
Cash	5.41K	-	-	40.58K	78.51K	267.65K	1.72M	4.16M	8.71M
Total Debt	-	-	-	-	667.93K	1.53M	-	322.27K	4.00M
Net Debt	-	-	-	-	589.42K	1.26M	-1.72M	-3.84M	-4.71M

Cash Flow

Currency: USD	2010-12-31	2015-12-31	2016-12-31	2017-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.20M	-3.10K	-3.10K	-65.99K	-1.45M	-1.06M	-4.16M	-10.25M	-22.78M
Investing Cash Flow	-	-	-	-	-	-	-	-	-4.62M
Financing Cash Flow	1.21M	3.10K	3.10K	106.58K	882.38K	1.25M	5.61M	12.69M	31.94M
Capital Expenditure	0	0	0	0	0	0	0	0	0
Free Cash Flow	-	-	-	-	-1.45M	-1.06M	-4.16M	-10.25M	-22.78M
FCF to OCF	-	-	-	-	100.00%	100.00%	100.00%	100.00%	100.00%

Earnings

Report Date	Feb 28, 2024	May 31, 2024	Aug 23, 2024	Nov 27, 2024	Feb 26, 2025	May 12, 2025	Aug 11, 2025	Nov 14, 2025	Mar 30, 2026	May 14, 2026	Aug 12, 2026	Nov 13, 2026
EPS Estimate	-	-	-	0.00	-0.32	-0.21	-0.26	-0.38	-0.25	-0.22	-0.14	-0.17
EPS Actual	-0.23	-0.16	-0.37	-0.31	-0.14	-0.42	-0.42	-1.09	-0.44	-0.30	-0.21	-
Surprise	-	-	-	-	55.56%	-100.00%	-61.54%	-186.84%	-77.68%	-36.36%	-50.00%	-
Timing	-	-	-	-	-	After-hours	After-hours	After-hours	-	After-hours	After-hours	-

Key Statistics & Ratios

Market Cap10.93M

Enterprise Value17.89M

Trailing P/E0.00

Forward P/E0.00

PEG Ratio0.00

Price / Sales0.00

Price / Book11.97

EPS-2.36

Book Value-0.029

Revenue (TTM)0

Gross Profit (TTM)0

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-7446.11%

Return on Assets-110.67%

Shares Outstanding71.71M

Shares Float52.61M

Beta-0.48

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Ownership Breakdown

Institutions: 4.15%
Insiders: 22.60%
Retail / Other: 73.25%

Top Institutional Holders

Interchange Capital Partners, LLC
1.59M2.51%
Sterling Investment Advisors Ltd
100.00K0.16%
Virtu Financial LLC
74.05K0.12%
Commonwealth Equity Services, LLC
52.64K0.08%
Bryn Mawr Trust Company
51.24K0.08%
May Hill Capital, LLC
50.62K0.08%
UBS Group AG
40.44K0.06%
BlackRock Inc
37.29K0.06%
Citadel Advisors Llc
25.10K0.04%
Stratos Wealth Partners, LTD
20.95K0.03%
LPL Financial Corp
15.61K0.02%
TWO SIGMA SECURITIES, LLC
15.62K0.02%
Marathon Capital Management LLC
15.50K0.02%
StoneX Group Inc
15.17K0.02%
Smithfield Trust Co
11.48K0.02%
Advisor Group Holdings, Inc.
8.50K0.01%
Morgan Stanley - Brokerage Accounts
5.47K0.01%
Mercer Global Advisors Inc.
5000.00%
HAZLETT, BURT & WATSON, INC.
4250.00%

Top Fund Holders

1290 VT Micro Cap K
2.74K0.00%

Stock Splits

Oct 12, 20261:50